518 related articles for article (PubMed ID: 17449988)
1. Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
Portenoy RK; Farrar JT; Backonja MM; Cleeland CS; Yang K; Friedman M; Colucci SV; Richards P
Clin J Pain; 2007 May; 23(4):287-99. PubMed ID: 17449988
[TBL] [Abstract][Full Text] [Related]
2. Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials.
Likar R; Kayser H; Sittl R
Clin Ther; 2006 Jun; 28(6):943-52. PubMed ID: 16860176
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
Aqua K; Gimbel JS; Singla N; Ma T; Ahdieh H; Kerwin R
Clin Ther; 2007 Jun; 29(6):1000-12. PubMed ID: 17692717
[TBL] [Abstract][Full Text] [Related]
5. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
6. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
Rog DJ; Nurmikko TJ; Young CA
Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
[TBL] [Abstract][Full Text] [Related]
7. Randomized trial comparing polymer-coated extended-release morphine sulfate to controlled-release oxycodone HCl in moderate to severe nonmalignant pain.
Nicholson B; Ross E; Sasaki J; Weil A
Curr Med Res Opin; 2006 Aug; 22(8):1503-14. PubMed ID: 16870075
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
9. Use of oxycodone controlled-release immediately after NSAIDs: a new approach to obtain good pain control.
Tessaro L; Bandieri E; Costa G; Fornasier G; Iorno V; Pizza C; Pastacaldi G; Micheletto G
Eur Rev Med Pharmacol Sci; 2010 Feb; 14(2):113-21. PubMed ID: 20329570
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study.
Muriel C; Failde I; Micó JA; Neira M; Sánchez-Magro I
Clin Ther; 2005 Apr; 27(4):451-62. PubMed ID: 15922818
[TBL] [Abstract][Full Text] [Related]
11. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
Simpson DM; Messina J; Xie F; Hale M
Clin Ther; 2007 Apr; 29(4):588-601. PubMed ID: 17617282
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of cancer pain management with controlled-release oxycodone tablets in opioid-naive cancer pain patients, starting with 5 mg tablets.
Koizumi W; Toma H; Watanabe K; Katayama K; Kawahara M; Matsui K; Takiuchi H; Yoshino K; Araki N; Kodama K; Kimura H; Kono I; Hasegawa H; Hatanaka K; Hiraga K; Takeda F
Jpn J Clin Oncol; 2004 Oct; 34(10):608-14. PubMed ID: 15591459
[TBL] [Abstract][Full Text] [Related]
13. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
14. Transdermal buprenorphine patches applied in a 4-day regimen versus a 3-day regimen: a single-site, Phase III, randomized, open-label, crossover comparison.
Likar R; Lorenz V; Korak-Leiter M; Kager I; Sittl R
Clin Ther; 2007 Aug; 29(8):1591-606. PubMed ID: 17919542
[TBL] [Abstract][Full Text] [Related]
15. Analgesic efficacy of controlled-release oxycodone in patients with uterine or ovarian cancer.
Suzuki T; Morishita M; Ito E; Matsuura M; Tanaka R; Saito T
Am J Ther; 2008; 15(1):31-5. PubMed ID: 18223351
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological approach to chronic visceral pain. Focus on oxycodone controlled release: an open multicentric study.
Liguori S; Gottardi M; Micheletto G; Bruno L
Eur Rev Med Pharmacol Sci; 2010 Mar; 14(3):185-90. PubMed ID: 20391956
[TBL] [Abstract][Full Text] [Related]
17. A randomized study to demonstrate noninferiority of once-daily OROS(®) hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain.
Binsfeld H; Szczepanski L; Waechter S; Richarz U; Sabatowski R
Pain Pract; 2010; 10(5):404-15. PubMed ID: 20384968
[TBL] [Abstract][Full Text] [Related]
18. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
Miner JR; Moore J; Gray RO; Skinner L; Biros MH
Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
[TBL] [Abstract][Full Text] [Related]
19. Clinical outcomes during opioid titration following initiation with or conversion to Remoxy®, an extended-release formulation of oxycodone.
Roland CL; Setnik B; Cleveland JM; Brown DA
Postgrad Med; 2011 Jul; 123(4):148-59. PubMed ID: 21680999
[TBL] [Abstract][Full Text] [Related]
20. Oxymorphone extended release for the treatment of chronic low back pain: a retrospective pooled analysis of enriched-enrollment clinical trial data stratified according to age, sex, and prior opioid use.
Peniston JH; Gould E
Clin Ther; 2009 Feb; 31(2):347-59. PubMed ID: 19302907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]